ZYUS Life Sciences Corporation Announces Planned Release Date for Phase 2a Clinical Trial Results, Annual General Meeting Results and Change in Audit Committee Chair

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

SASKATOON, SK, Sept. 24, 2026 /CNW/ -- ZYUS Life Sciences Corporation (the "ZYUS" and or "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel drug product candidates for chronic pain is pleased to announce that it anticipates announcing topline results from its Phase 2a UTOPIA-1 clinical trial on September 30, 2026. In addition, the Company is pleased to announce the results of its Annual General and Special Meeting of Shareholders (the "Meeting") held on September 24, 2026, including the election of the Company's directors, the appointment of its external auditor and approval of its Omnibus Equity Incentive Plan. The Company further announces a change in the Chair of the Company's Audit Committee.

Anticipated Timing of Phase 2a UTOPIA-1 Topline Results

The Company expects to announce topline results from its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial on September 30, 2026. The Phase 2a UTOPIA-1 trial evaluated Trichomylin^® softgel capsules in patients experiencing moderate to severe cancer-related pain. 

Annual General and Special Meeting Results and Appointment of External Auditor

At the Meeting, shareholders voted in favour of all matters presented for approval. Shareholders elected each of the nominees listed in the Company's management information circular dated August 14, 2026 as directors of the Company, with each director to hold office until the next annual meeting of shareholders or until their successor is duly elected or appointed. The Board of Directors (the "Board") continues to be comprised of six (6) directors: Brent H. Zettl, Richard Hoyt, John L. Knowles, Garnette Weber, Dr. Charlotte Moore Hepburn, and Wayne Brownlee.

Shareholders of the Company also approved the appointment of MNP LLP, Chartered Professional Accountants as external auditors of the Company and authorized the directors to fix the auditor's remuneration. In addition, shareholders also ratified, confirmed and approved the Company's Omnibus Equity Incentive Plan.

Change in Audit Committee Chair

The Company is also pleased to announce that Wayne Brownlee has been appointed Chair of the Audit Committee, replacing John L. Knowles, effective September 24, 2026.

Mr. Knowles was appointed Interim Chief Financial Officer of the Company effective September 14, 2026 and, in connection with his appointment, has stepped down as Chair of the Audit Committee. Mr. Knowles will continue to serve as a member of the Company's Board and as a member of the Audit Committee.

Mr. Brownlee is the former Executive Vice-President and Chief Financial Officer of Potash Corporation of Saskatchewan Inc. and Nutrien Ltd., and brings extensive experience in corporate finance, business leadership, and governance. He is a Member of the Order of Canada (C.M.) and a recipient of the Saskatchewan Order of Merit (S.O.M.).

As Chair of the Audit Committee, Mr. Brownlee will oversee the Committee's responsibilities relating to financial reporting, internal controls, risk management, and oversight of the Company's external auditor.

"We are pleased to have Mr. Brownlee assume the role of Audit Committee Chair," said Brent Zettl, President and Chief Executive Officer of ZYUS. "We thank Mr. Knowles for his leadership of the Audit Committee and look forward to his continued contribution to ZYUS as a member of the Board and in his role as Interim Chief Financial Officer."

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a clinical stage life sciences company focused on the development and commercialization of novel, non-opioid pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit www.zyus.com or follow us on X @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's expectations with respect to the release of its Phase 2a UTOPIA-1 results, the change in the Audit Committee chair, the change in auditor, the Company's clinical and corporate objectives, and the anticipated role and responsibilities of the Company's management, Board of Directors and Audit Committee.

Often, but not always, forward-looking statements can be identified by the use of words such as "expects", "expected", "expectation", "anticipates", "believes", "intends," "estimates", "predicts", "continues", "potential", "targeted", "plans", "possible" and similar expressions, or statements that events, conditions or results "will," "may," "could," "would" or "should" occur or be achieved, or the negative of these terms or other comparable terminology.

Forward-looking statements in this news release are based on certain assumptions, including that the announcement of the Phase 2a UTOPIA-1 results will occur when anticipated, that the new Audit Committee chair and Interim Chief Financial Officer will effectively oversee the Company's financial reporting, accounting, auditor oversight and corporate finance functions, and that the Company's management and Board of Directors will be able to execute their respective responsibilities in support of the Company's clinical and corporate objectives. Such forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Readers are cautioned that the foregoing list of factors, assumptions, and risks is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements or information, whether written or oral, that may be made from time to time by the Company or on its behalf, except as required by applicable law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE ZYUS Life Sciences Corporation

For more information, please contact: ZYUS Media Inquiries: [email protected], 1-833-651-7723; ZYUS Investor Relations: [email protected]